Literature DB >> 1914609

Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids.

G U Meduri1, J M Belenchia, R J Estes, R G Wunderink, M el Torky, K V Leeper.   

Abstract

Most patients with adult respiratory distress syndrome (ARDS) survive the initial insult which caused respiratory failure only to succumb later to sepsis caused by nosocomial pneumonia or to pulmonary fibrosis. Clinical criteria and analysis of the tracheal aspirate are notoriously inadequate for establishing a diagnosis of ventilator-associated pneumonia. We implemented a comprehensive diagnostic protocol to determine the cause of sepsis in ARDS patients who had been ventilated for more than three days and who had no bronchoscopic evidence of pneumonia. Nine patients with late ARDS who had fever (89 percent), leukocytosis (89 percent), a new localized infiltrate (78 percent), purulent tracheal secretions (89 percent), low systemic vascular resistance (50 percent), and marked uptake of gallium in the lungs (100 percent) had no source of infection identified. Open-lung biopsy specimens from seven patients showed the fibroproliferative phase of diffuse alveolar damage and confirmed absence of pneumonia. Treatment with prolonged high doses of corticosteroids was associated with a marked and rapid improvement in lung injury score (p less than 0.003 at five days). Our findings indicate that the fibroproliferative process occurring in the lungs of patients with late ARDS gives rise to clinical manifestations identical to those of pneumonia and is potentially responsive to steroid treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914609     DOI: 10.1378/chest.100.4.943

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  42 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

Review 2.  The pulmonary physician and critical care. 2. The injured lung: conventional and novel respiratory therapy.

Authors:  A Swami; B F Keogh
Journal:  Thorax       Date:  1992-07       Impact factor: 9.139

Review 3.  The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.

Authors:  M Messent; M J Griffiths
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

Review 4.  [Corticosteroid administration for acute respiratory distress syndrome : therapeutic option?].

Authors:  P Möhnle; J Briegel
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

5.  Acute respiratory distress syndrome: a historical perspective.

Authors:  Gordon R Bernard
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

6.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 7.  Evaluation of the available invasive and non-invasive techniques for diagnosing nosocomial pneumonias in mechanically ventilated patients.

Authors:  A Torres; J González; M Ferrer
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

8.  The clinical use of 99m-Tc-labeled WBC scintigraphy in critically ill surgical and trauma patients with occult sepsis.

Authors:  G Minoja; M Chiaranda; A Fachinetti; M Raso; L Dominioni; D Torre; D De Palma
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 9.  Prevention and therapy of the adult respiratory distress syndrome.

Authors:  B Temmesfeld-Wollbrück; D Walmrath; F Grimminger; W Seeger
Journal:  Lung       Date:  1995       Impact factor: 2.584

10.  Low-dose steroids in adult septic shock: results of the Surviving Sepsis Campaign.

Authors:  Brian Casserly; Herwig Gerlach; Gary S Phillips; Stanley Lemeshow; John C Marshall; Tiffany M Osborn; Mitchell M Levy
Journal:  Intensive Care Med       Date:  2012-10-12       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.